| Updated research nosology for HIV-associated neurocognitive disorders A Antinori, G Arendt, JT Becker, BJ Brew, DA Byrd, M Cherner, DB Clifford, ... Neurology 69 (18), 1789-1799, 2007 | 3202 | 2007 |
| Combination antiretroviral therapy and the risk of myocardial infarction Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group New England Journal of Medicine 349 (21), 1993-2003, 2003 | 2139 | 2003 |
| Monkeypox virus infection in humans across 16 countries—April–June 2022 JP Thornhill, S Barkati, S Walmsley, J Rockstroh, A Antinori, LB Harrison, ... New England Journal of Medicine 387 (8), 679-691, 2022 | 1953 | 2022 |
| Liver-related deaths in persons infected with the human immunodeficiency virus: the D: A: D study Data Collection on Adverse Events of Anti-HIV Drugs Study Group Archives of internal medicine 166 (15), 1632-1641, 2006 | 1512 | 2006 |
| Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D: A: D study: a multi-cohort collaboration D: A: D Study Group The Lancet 371 (9622), 1417-1426, 2008 | 1190 | 2008 |
| Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of … AJ Rodger, V Cambiano, T Bruun, P Vernazza, S Collins, O Degen, ... The Lancet 393 (10189), 2428-2438, 2019 | 1189 | 2019 |
| Mapping the human genetic architecture of COVID-19 Writing group Writing group leaders Pathak Gita A. 6 Andrews Shea J. 7 Kanai ... Nature 600 (7889), 472-477, 2021 | 848 | 2021 |
| Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients AA Monforte, AC Lepri, G Rezza, P Pezzotti, A Antinori, AN Phillips, ... Aids 14 (5), 499-507, 2000 | 777 | 2000 |
| Correlates and predictors of adherence to highly active antiretroviral therapy: overview of published literature. Ammassari | 677 | 2002 |
| Self-reported symptoms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV infection A Ammassari, R Murri, P Pezzotti, MP Trotta, L Ravasio, P De Longis, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 28 (5), 445-449, 2001 | 675 | 2001 |
| Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b … B Clotet, J Feinberg, J van Lunzen, MA Khuong-Josses, A Antinori, ... The Lancet 383 (9936), 2222-2231, 2014 | 652 | 2014 |
| Late presentation of HIV infection: a consensus definition A Antinori, T Coenen, D Costagiola, N Dedes, M Ellefson, J Gatell, ... HIV medicine 12 (1), 61-64, 2011 | 646 | 2011 |
| Epidemiological, clinical and virological characteristics of four cases of monkeypox support transmission through sexual contact, Italy, May 2022 A Antinori, V Mazzotta, S Vita, F Carletti, D Tacconi, LE Lapini, ... Eurosurveillance 27 (22), 2200421, 2022 | 595 | 2022 |
| Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a … L Wittkop, HF Günthard, F De Wolf, D Dunn, A Cozzi-Lepri, A De Luca, ... The Lancet infectious diseases 11 (5), 363-371, 2011 | 475 | 2011 |
| Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study N Friis-Møller, R Thiebaut, P Reiss, R Weber, A D'Arminio Monforte, ... European journal of cardiovascular prevention & rehabilitation 17 (5), 491-501, 2010 | 475 | 2010 |
| Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2 … P Cahn, JS Madero, JR Arribas, A Antinori, R Ortiz, AE Clarke, CC Hung, ... The Lancet 393 (10167), 143-155, 2019 | 446 | 2019 |
| Persistence of neuropsychologic deficits despite long-term highly active antiretroviral therapy in patients with HIV-related neurocognitive impairment: prevalence and risk factors V Tozzi, P Balestra, R Bellagamba, A Corpolongo, MF Salvatori, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 45 (2), 174-182, 2007 | 435 | 2007 |
| Depressive symptoms, neurocognitive impairment, and adherence to highly active antiretroviral therapy among HIV-infected persons A Ammassari, A Antinori, MS Aloisi, MP Trotta, R Murri, L Bartoli, ... Psychosomatics 45 (5), 394-402, 2004 | 399 | 2004 |
| Depression is a risk factor for suboptimal adherence to highly active antiretroviral therapy F Starace, A Ammassari, MP Trotta, R Murri, P De Longis, C Izzo, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 31, S136-S139, 2002 | 372 | 2002 |
| Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection … PE Sax, A Pozniak, ML Montes, E Koenig, E DeJesus, HJ Stellbrink, ... The Lancet 390 (10107), 2073-2082, 2017 | 351 | 2017 |
Adriana AmmassariHIV/AIDS Unit - INMI - National Institute for Infectious Diseases L. Spallanzani, RomaPatvirtintas el. paštas inmi.it